ZEVRA THERAPEUTICS, INC. (ZVRA)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch ZVRA
See up to 3 months of ZVRA. The 7-day demo opens the 1M and 3M ranges and puts ZVRA on your watchlist.
Start 7-day demoLatest ZVRA insider trades
About ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. is an SEC registrant, filing under CIK 0001434647, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ZVRA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 74,966 | $838K |
| Option exercise | 4 | 124,600 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ZVRA insider transactions (Form 4)
6529 Form 4 filings on record, the earliest from Oct 16, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Neil F. McFarlane - Officer | Option exercise | Common Stock | 50,000 | - footnote F1 | - | |
| Neil F. McFarlane - Officer | Open-market sale | Common Stock | 20,000 | $11.25 footnote F3 | $225K | |
| Neil F. McFarlane - Officer | Option exercise | Restricted Stock Unit | 50,000 | $0.00 | - | |
| ||||||
| Rahsaan Thompson - Officer | Open-market sale | Common Stock | 42,666 | $11.13 footnote F2 | $475K | |
| ||||||
| Corey Michael Watton - Director | Option exercise | Common Stock | 12,300 | $4.97 | $61K | |
| Corey Michael Watton - Director | Open-market sale | Common Stock | 12,300 | $11.25 footnote F1 | $138K | |
| Corey Michael Watton - Director | Option exercise | Stock Option (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| Rahsaan Thompson - Officer | Open-market sale | Common Stock | 34,557 | $12.68 footnote F3 | $438K | |
| Rahsaan Thompson - Officer | Option exercise | Restricted Stock Unit | 66,667 | $0.00 | - | |
| Rahsaan Thompson - Officer | Option exercise | Common Stock | 66,667 | - footnote F1 | - | |
| ||||||
| Tamara A. Favorito - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
 Alicia Secor - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
| Corey Michael Watton - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
| Douglas W. Calder - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
 Thomas Anderson - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
 Alvin Shih - Director | Grant or award | Stock Option (right to buy) | 30,000 footnote F2 | $0.00 | - | |
| ||||||
| Timothy J. Sangiovanni - Officer | Grant or award | Stock Option (right to buy) | 40,000 | $0.00 | - | |
| Timothy J. Sangiovanni - Officer | Grant or award | Restricted Stock Unit | 20,000 | $0.00 | - | |
| Rahsaan Thompson - Officer | Open-market sale | Common Stock | 1,794 | $11.30 | $20K | |
 John B. Bode - Director | Option exercise | Common Stock | 39,200 | $4.97 | $195K | |
| John B. Bode - Director | Option exercise | Common Stock | 39,200 | $4.89 | $192K | |
| John B. Bode - Director | Option exercise | Stock Option (right to buy) | 39,200 | $0.00 | - | |
| John B. Bode - Director | Option exercise | Stock Option (right to buy) | 39,200 | $0.00 | - | |
| Justin A. Renz - Officer | Grant or award | Stock Option (right to buy) | 300,000 | $0.00 | - | |
| Neil F. McFarlane - Officer | Option exercise | Common Stock | 37,500 | - footnote F1 | - | |
| Neil F. McFarlane - Officer | Open-market sale | Common Stock | 14,625 | $8.56 footnote F3 | $125K | |
| Neil F. McFarlane - Officer | Option exercise | Restricted Stock Unit | 37,500 | $0.00 | - | |
| ||||||
| Timothy J. Sangiovanni - Officer | Open-market sale | Common Stock | 3,000 | $9.18 footnote F2 | $28K | |
| ||||||
| Joshua Schafer - Officer | Open-market sale | Common Stock | 10,500 | $9.19 footnote F2 | $97K | |
| ||||||
| Timothy J. Sangiovanni - Officer | Option exercise | Common Stock | 6,333 | - footnote F1 | - | |
| Timothy J. Sangiovanni - Officer | Open-market sale | Common Stock | 1,750 | $8.82 footnote F3 | $15K | |
| Timothy J. Sangiovanni - Officer | Option exercise | Common Stock | 11,666 | - footnote F1 | - | |
| Timothy J. Sangiovanni - Officer | Option exercise | Restricted Stock Unit | 6,333 | $0.00 | - | |
| Timothy J. Sangiovanni - Officer | Option exercise | Restricted Stock Unit | 11,666 | $0.00 | - | |
| ||||||
| Rahsaan Thompson - Officer | Option exercise | Common Stock | 11,333 | - footnote F1 | - | |
| Rahsaan Thompson - Officer | Open-market sale | Common Stock | 4,080 | $8.83 footnote F3 | $36K | |
| Rahsaan Thompson - Officer | Grant or award | Restricted Stock Unit | 37,500 | $0.00 | - | |
| Rahsaan Thompson - Officer | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Rahsaan Thompson - Officer | Option exercise | Restricted Stock Unit | 11,333 | $0.00 | - | |
| ||||||
| Adrian W. Quartel - Officer | Option exercise | Common Stock | 11,333 | - footnote F1 | - | |
| Adrian W. Quartel - Officer | Open-market sale | Common Stock | 4,533 | $8.83 footnote F3 | $40K | |
| Adrian W. Quartel - Officer | Grant or award | Restricted Stock Unit | 37,500 | $0.00 | - | |
| Adrian W. Quartel - Officer | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Adrian W. Quartel - Officer | Option exercise | Restricted Stock Unit | 11,333 | $0.00 | - | |
| ||||||
| Joshua Schafer - Officer | Option exercise | Common Stock | 11,333 | - footnote F1 | - | |
| Joshua Schafer - Officer | Open-market sale | Common Stock | 3,375 | $8.83 footnote F3 | $30K | |
| Joshua Schafer - Officer | Option exercise | Common Stock | 35,334 | - footnote F1 | - | |
| Joshua Schafer - Officer | Grant or award | Restricted Stock Unit | 37,500 | $0.00 | - | |
| Joshua Schafer - Officer | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Joshua Schafer - Officer | Option exercise | Restricted Stock Unit | 11,333 | $0.00 | - | |
| Joshua Schafer - Officer | Option exercise | Restricted Stock Unit | 35,334 | $0.00 | - | |
| ||||||
| Neil F. McFarlane - Officer | Option exercise | Common Stock | 233,334 | - footnote F1 | - | |
| Neil F. McFarlane - Officer | Grant or award | Stock Option (right to buy) | 250,000 | $0.00 | - | |
| Neil F. McFarlane - Officer | Option exercise | Restricted Stock Unit | 233,334 | $0.00 | - | |
| Neil F. McFarlane - Officer | Open-market sale | Common Stock | 91,000 | $9.38 footnote F3 | $853K | |
| Neil F. McFarlane - Officer | Grant or award | Restricted Stock Unit | 125,000 | $0.00 | - | |
| ||||||
| Neil F. McFarlane - Officer | Option exercise | Common Stock | 50,000 | - footnote F1 | - | |
| Neil F. McFarlane - Officer | Open-market sale | Common Stock | 19,500 | $10.82 | $211K | |
| Neil F. McFarlane - Officer | Option exercise | Restricted Stock Unit | 50,000 | $0.00 | - | |
| ||||||
| Tamara A. Favorito - Director | Open-market purchase | Common Stock | 3,175 | $7.79 | $25K | |
| Alvin Shih - Director | Open-market purchase | Common Stock | 20,000 | $7.89 | $158K | |
| John B. Bode - Director | Open-market purchase | Common Stock | 5,000 | $9.17 | $46K | |
| Tamara A. Favorito - Director | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Wendy L. Dixon - Director | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Corey Michael Watton - Director | Open-market purchase | Common Stock | 500 | $7.92 | $4K | |
Item 2.02, 9.01
Item 5.07, 9.01
Item 2.02, 9.01
Item 1.01, 1.02, 7.01, 9.01
Recent ZVRA Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Neil F. McFarlane | Director, Officer | 20,000 | $228K | View on EDGAR | |
| Rahsaan Thompson | Officer, Secretary | 42,666 |
ZVRA insider trading FAQ
What is the latest insider trade for ZVRA?
ZEVRA THERAPEUTICS, INC. (ZVRA) had 3 insider filings in the last 90 days, with the most recent on 13 October 2026. The full record for ZVRA runs to 29 Form 4 filings, the earliest from 16 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ZVRA stock?
No insider purchases of ZVRA were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling ZVRA stock?
3 insider sales of ZVRA were filed in the last 90 days, totaling $838K.
Where can I see ZVRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ZVRA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Neil F. McFarlane view on EDGAR
- - Rahsaan Thompson view on EDGAR
- - Corey Michael Watton view on EDGAR
- - Rahsaan Thompson view on EDGAR
- - Tamara A. Favorito view on EDGAR
- - Alicia Secor view on EDGAR
- - Corey Michael Watton view on EDGAR
- - Douglas W. Calder view on EDGAR
- - Thomas Anderson view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ZVRA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ZVRA with a 7-day demo
- ZVRA on your watchlist
- Every ZVRA Form 4 filing on record
- Up to 3 months of ZVRA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
